ArticleBMC pediatrics2025
Functional identification of two variants in unrelated Chinese patients with DNM1L-related mitochondrial disorders.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe DRP1 protein, a member of the dynamin superfamily of GTPases, is encoded by the dynamin-1-like (DNM1L) gene and plays a critical role in mitochondrial fission. There was significant clinical heterogeneity in DNM1L-related disorders.
methodsWhole exome sequencing (WES) was used to identify potential genetic causes of the phenotype in probands. Bioinformatics analysis was performed to analyze the pathogenicity of the identified variants, and 3D protein modeling was constructed to predict their effects on protein structure. Preliminary studies of the functional effects of the variant sites on the encoded proteins were performed by in vitro experiments.
resultsTwo de novo variants, c.1049G>C (p.Gly350Ala) and c.2161C>T (p.Gln721*), were detected in affected individuals. One patient presented with severe epileptic encephalopathy while the other exhibited a distinctive clinical phenotype of hemiparesis. In silico analysis, conservative analysis, and 3D homology modelling indicated that the p.Gly350Ala and the p.Gln721* variants are deleterious. Furthermore, the results of the artificial transfection experiments demonstrated that the p.Gly350Ala variant resulted in a reduction in DNM1L expression at both the transcriptional and protein levels (p < 0.05). In contrast, the p.Gln721* variant exhibited no significant alteration in protein levels (p = 0.08), although it did result in a reduction in mRNA levels.
conclusionsThe present findings suggest that these variants may contribute to DRP1 deficiency, potentially triggering a range of DNM1L-related disease phenotypes. This study serves to expand the spectrum of variants associated with DNM1L-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.